204 related articles for article (PubMed ID: 38474199)
1. A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions.
Enzler T; Shi J; McGue J; Griffith BD; Sun L; Sahai V; Nathan H; Frankel TL
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474199
[TBL] [Abstract][Full Text] [Related]
2. Expression of PD-L1 and VISTA in Intraductal Papillary Mucinous Neoplasm With Associated Invasive Carcinoma of the Pancreas.
Mo S; Zou L; Hu Y; Chang X; Chen J
Mod Pathol; 2023 Sep; 36(9):100223. PubMed ID: 37244388
[TBL] [Abstract][Full Text] [Related]
3. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
4. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
5. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
6. Functional reprogramming of peripheral blood monocytes by soluble mediators in patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
Eckhoff AM; Brown MC; Landa K; Naqvi I; Holl EK; Boczkowski D; Fletcher A; Rhodin KE; Giang MH; Sullenger B; Beasley GM; Allen PJ; Nair SK
Front Immunol; 2023; 14():1116034. PubMed ID: 37575220
[TBL] [Abstract][Full Text] [Related]
7. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival.
Yan H; Qiu W; Koehne de Gonzalez AK; Wei JS; Tu M; Xi CH; Yang YR; Peng YP; Tsai WY; Remotti HE; Miao Y; Su GH
Cancer Lett; 2019 Feb; 442():333-340. PubMed ID: 30447255
[TBL] [Abstract][Full Text] [Related]
8. Surveillance for pancreatic cancer in high-risk individuals.
Konings ICAW; Canto MI; Almario JA; Harinck F; Saxena P; Lucas AL; Kastrinos F; Whitcomb DC; Brand RE; Lachter J; Malleo G; Paiella S; Syngal S; Saltzman JR; Stoffel EM; van Hooft JE; Hruban RH; Poley JW; Fockens P; Goggins MG; Bruno MJ;
BJS Open; 2019 Oct; 3(5):656-665. PubMed ID: 31592073
[TBL] [Abstract][Full Text] [Related]
9. High-grade pancreatic intraepithelial lesions: prevalence and implications in pancreatic neoplasia.
Park JR; Li F; Oza VM; Sklaw BC; Cronley KM; Wellner M; Swanson B; Krishna SG
Hepatobiliary Pancreat Dis Int; 2017 Apr; 16(2):202-208. PubMed ID: 28381386
[TBL] [Abstract][Full Text] [Related]
10. Precursor lesions of pancreatic cancer.
Yonezawa S; Higashi M; Yamada N; Goto M
Gut Liver; 2008 Dec; 2(3):137-54. PubMed ID: 20485640
[TBL] [Abstract][Full Text] [Related]
11. Characterization and digital spatial deconvolution of the immune microenvironment of intraductal oncocytic papillary neoplasms (IOPN) of the pancreas.
Pea A; Paolino G; Martelli F; Bariani E; Piccoli P; Sereni E; Salvia R; Lawlor RT; Cheng L; Chang D; Scarpa A; Luchini C
Virchows Arch; 2023 Aug; 483(2):157-165. PubMed ID: 37086293
[TBL] [Abstract][Full Text] [Related]
12. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.
Diana A; Wang LM; D'Costa Z; Allen P; Azad A; Silva MA; Soonawalla Z; Liu S; McKenna WG; Muschel RJ; Fokas E
Oncotarget; 2016 Jul; 7(27):40992-41004. PubMed ID: 27329602
[TBL] [Abstract][Full Text] [Related]
14. Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer.
Ohya A; Yamanoi K; Shimojo H; Fujii C; Nakayama J
Cancer Sci; 2017 Sep; 108(9):1897-1902. PubMed ID: 28685935
[TBL] [Abstract][Full Text] [Related]
15. Outcome after surgery for invasive intraductal papillary mucinous neoplasia compared to conventional pancreatic ductal adenocarcinoma - A Swedish nationwide register-based study.
Holmberg M; Radkiewicz C; Strömberg C; Öman M; Ghorbani P; Löhr JM; Sparrelid E
Pancreatology; 2023 Jan; 23(1):90-97. PubMed ID: 36522260
[TBL] [Abstract][Full Text] [Related]
16. Single-cell RNA sequencing highlights epithelial and microenvironmental heterogeneity in malignant progression of pancreatic ductal adenocarcinoma.
Li J; Wei T; Ma K; Zhang J; Lu J; Zhao J; Huang J; Zeng T; Xie Y; Liang Y; Li X; Zhang Q; Liang T
Cancer Lett; 2024 Mar; 584():216607. PubMed ID: 38246225
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
Fukuda A
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
[TBL] [Abstract][Full Text] [Related]
18. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
[TBL] [Abstract][Full Text] [Related]
19. mAb Das-1 identifies pancreatic ductal adenocarcinoma and high-grade pancreatic intraepithelial neoplasia with high accuracy.
Das KK; Brown JW; Fernandez Del-Castillo C; Huynh T; Mills JC; Matsuda Y; Das KM; Mino-Kenudson M
Hum Pathol; 2021 May; 111():36-44. PubMed ID: 33524436
[TBL] [Abstract][Full Text] [Related]
20. Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.
Danilova L; Ho WJ; Zhu Q; Vithayathil T; De Jesus-Acosta A; Azad NS; Laheru DA; Fertig EJ; Anders R; Jaffee EM; Yarchoan M
Cancer Immunol Res; 2019 Jun; 7(6):886-895. PubMed ID: 31043417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
